Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers

Executive Summary

Europe's IPO window remains closed but the region still attracts U.S. investors; drug spending set to decline in Greece and Spain in 2014; Pfizer takes Bosulif off the German market because agreement on price unlikely with health insurers; no room for value-based pricing in the U.K.; European Parliament clears €80 billion in research funding under Horizon 2020.

Advertisement

Related Content

Egalet Lines Up Cash In Deal With Japan’s Shionogi Ahead Of IPO
German Pharma Balks As Second HTA Retrospective Assessment Includes Orphan Drugs
Pfizer’s Bosulif Too Expensive And Lacks Data, Says NICE
European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel